Share price · CYTK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CYTK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-12.7%
- 5 Oct 2026-4.4%
- 8 Sep 2026+3.6%
Nothing announced by CYTK that day or the session before.
- 7 Aug 2026-5.7%
- 16 Jun 2026+5.4%
Nothing announced by CYTK that day or the session before.
- 5 May 2026+16.7%
- 30 Apr 2026+7.4%
Nothing announced by CYTK that day or the session before.
- 27 Apr 2026-5.7%
Nothing announced by CYTK that day or the session before.
- 25 Feb 2026-10.3%
- 18 Dec 2025+4.0%
Nothing announced by CYTK that day or the session before.
Share of unusual movement by asset
For each asset, the share of CYTK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Aficamten(Myqorzo) | Approved | Cardiac myosin (inhibitor)Small molecule | Hypertrophic Cardiomyopathy |
| Phase 3 | Cardiac myosin (activator)Small molecule | Heart Failure Heart Failure with Reduced Ejection Fraction | |
| Phase 2 | Cardiac myosin (inhibitor)Small molecule | Heart Failure Heart Failure with Preserved Ejection Fraction | |
TirasemtivNo recent activity | Discontinued | Troponin complex (skeletal muscle fast fibers) | Indication not yet linked |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $48M | $99M | $203M+ $927M short-term inv. | $190M-$124M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $29M | $98M | $255M+ $910M short-term inv. | $199M-$160M operating cash flow | report ↗ |
| 2026-Q1 | $19M | $96M | $130M+ $689M short-term inv. | $206M-$145M operating cash flow | report ↗ |
| 2025-Q3 | $1.9M | $99M | $225M+ $737M short-term inv. | $306M-$108M operating cash flow | report ↗ |
| 2025-Q2 | $67M | $113M | $75M+ $783M short-term inv. | $134M-$128M operating cash flow | report ↗ |
| 2025-Q1 | $1.6M | $100M | $74M+ $865M short-term inv. | $161M-$132M operating cash flow | report ↗ |
| 2024-Q3 | $0.5M | $85M | $47M+ $965M short-term inv. | $161M-$102M operating cash flow | report ↗ |
| 2024-Q2 | $0.3M | $80M | $190M+ $867M short-term inv. | $143M-$99M operating cash flow | report ↗ |
| 2024-Q1 | $0.8M | $82M | $120M+ $499M short-term inv. | $136M-$130M operating cash flow | report ↗ |
| 2023-Q3 | $0.4M | $83M | $100M+ $440M short-term inv. | $129M-$96M operating cash flow | report ↗ |
| 2023-Q2 | $0.9M | $83M | $69M+ $497M short-term inv. | $129M-$122M operating cash flow | report ↗ |
| 2023-Q1 | $4.6M | $79M | $102M+ $562M short-term inv. | $131M-$122M operating cash flow | report ↗ |
| 2022-Q3 | $2.5M | $63M | $106M+ $761M short-term inv. | $142M-$84M operating cash flow | report ↗ |
| 2022-Q2 | $89M | $57M | $94M+ $492M short-term inv. | $20M-$90M operating cash flow | report ↗ |
| 2022-Q1 | $1.1M | $46M | $115M+ $494M short-term inv. | $89M-$27M operating cash flow | report ↗ |
| 2021-Q3 | $5.4M | $48M | $91M+ $387M short-term inv. | $76M-$39M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $88M | $416M | $123M+ $760M short-term inv. | $196M-$510M operating cash flow | report ↗ |
For fiscal 2025, Cytokinetics reported total revenue of $88.04M, up 376.7% YoY, and R&D spend of $416.03M, up 22.6% YoY. The company ended the year with approximately $1.22B in cash, cash equivalents and investments, and reported a net loss of $784.95M, with quarterly net burn of $784.96M.
Business developments included MYQORZO approvals in the U.S., China, and Europe, with the U.S. launch underway, and submission of a supplemental NDA for MAPLE-HCM. The company guided 2026 GAAP combined R&D and SG&A expense to $830M-$870M, expects topline results from ACACIA-HCM in Q2 2026, a Germany launch in Q2 2026, and potential FDA approval of the MAPLE-HCM sNDA in Q4 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $18M | $339M | $95M+ $981M short-term inv. | $147M-$396M operating cash flow | report ↗ |
| 2023-FY | $7.5M | $330M | $113M+ $502M short-term inv. | $132M-$414M operating cash flow | report ↗ |
| 2022-FY | $95M | $241M | $66M+ $717M short-term inv. | $97M-$300M operating cash flow | report ↗ |
| 2021-FY | $70M | $160M | $113M+ $359M short-term inv. | $54M-$143M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 90 sales ($52.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Hessekiel Jeffrey · Chief Legal & Admin Officer | Open-market sale | 15,106 | $52.62 | $795K | Form 4 |
| 2026-11-17 | Malik Fady Ibraham · EVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Form 4 |
| 2026-11-17 | Malik Fady Ibraham · EVP Research & Development | Open-market sale | 3,300 | $51.73 | $171K | Form 4 |
| 2026-11-17 | Malik Fady Ibraham · EVP Research & Development | Open-market sale | 200 | $52.59 | $11K | Form 4 |
| 2026-11-17 | Malik Fady Ibraham · EVP Research & Development | Option exercise (derivative) | 3,500 | — | — | Form 4 |
| 2026-11-16 | Blum Robert I · director, President & CEO | Option exercise | 7,500 | $10.60 | $80K | Form 4 |
| 2026-11-16 | Blum Robert I · director, President & CEO | Open-market sale | 5,077 | $53.22 | $270K | Form 4 |
| 2026-11-16 | Blum Robert I · director, President & CEO | Open-market sale | 2,223 | $54.08 | $120K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 435 reporting institutions held 146.2M shares ($8.3B, 117.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 16,548,011 | $1.1B |
| 2 | FMR LLC | 10,723,140 | $706.8M |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 8,009,489 | $527.9M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,843,782 | $385.2M |
| 5 | STATE STREET CORP | 5,745,193 | $378.7M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,488,634 | $361.8M |
| 7 | Avoro Capital Advisors LLC | 3,333,333 | $219.7M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 3,215,415 | $212.0M |
| 9 | BANK OF AMERICA CORP /DE/ | 3,125,436 | $206.0M |
| 10 | RTW INVESTMENTS, LP | 2,721,158 | $179.4M |
| 11 | GOLDMAN SACHS GROUP INC | 2,205,758 | $145.4M |
| 12 | UBS Group AG | 2,077,277 | $136.9M |
| 13 | Polar Capital Holdings Plc | 1,661,248 | $109.5M |
| 14 | Integral Health Asset Management, LLC | 1,600,000 | $105.5M |
| 15 | MORGAN STANLEY | 1,505,075 | $99.2M |